Bio Pharma Dive
AUGUST 10, 2021
Deals were few and far between last quarter. But the recent history of biopharma M&A suggests they'll return. Keep track of them as as they happen with BioPharma Dive's new database.
World of DTC Marketing
AUGUST 10, 2021
SUMMARY : Falsehoods have been shown to spread faster and farther than accurate information, and research suggests that misinformation can have negative effects in the real world, such as amplifying controversy about vaccines and propagating unproven cancer treatments. Therefore, health misinformation on social media urgently requires greater action from those working in public health research and practice.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
AUGUST 10, 2021
While Canada has already secured more COVID-19 vaccine doses than it needs, the factory to be built is geared toward combating future pandemics.
pharmaphorum
AUGUST 10, 2021
Europe market has proved so hostile to gene therapies when it comes to pricing and reimbursement for gene therapies that bluebird bio has decided to quit the market altogether, according to Andrew Obenshain, president of its severe genetic diseases unit. On the firm’s second-quarter results call, Obenshain said the biotech will start “an orderly wind-down” of its activities in Europe and seek “strategic alternatives” to make its therapies available to patients there
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
BioPharma Reporter
AUGUST 10, 2021
Pfizer and BioNTech are lining up orders of their COVID-19 vaccine for next year and beyond, predicting total capacity in 2022 to rise to 4 billion doses.
pharmaphorum
AUGUST 10, 2021
Oxford University and UK clinical artificial intelligence (AI) company Sensyne Health will partner on a project to find new drug targets for people with hard-to-treat asthma. It’s estimated that almost one in five people with asthma find it difficult to control symptoms using current therapies, while around 4% have particularly severe forms that puts them at risk of life-threatening attacks.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
pharmaphorum
AUGUST 10, 2021
BioNTech has suggested that giving booster doses of its current Comirnaty (BNT162b2) COVID-19 vaccine may be a preferable strategy to modifying the Pfizer-partnered shot. The comments came on the German biotech’s second-quarter results call, during which BioNTech raised its forecasts for revenues it will book from sales of the vaccine to €15.9 billion (almost $19 billion), on the back of contracts to deliver 2.2 billion doses this year with more than 1 billion already booked in for 2022.
Outsourcing Pharma
AUGUST 10, 2021
The University of Illinois at Chicago has been given $6m from the US Department of Defense to develop a potential treatment for severe cases of COVID-19.
BioSpace
AUGUST 10, 2021
?Moderna will construct a manufacturing facility in Canada to provide direct access to mRNA vaccines for the COVID-19 pandemic and future viral threats and respiratory viruses.
Triage Cancer
AUGUST 10, 2021
Have you ever been sure you picked an in-network provider for a treatment or test, but later received a surprisingly high bill? You may have experienced “surprise billing,” something that can leave patients paying unnecessarily high bills, facing debts, and fielding calls from collection agencies. . A “surprise bill” happens when a patient has done their due diligence by picking a health care provider and hospital within their network, but learns after receiving treatment that a certain member
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
BioPharma Reporter
AUGUST 10, 2021
The pharma firm is working with five US colleges and universities onto create programming designed to boost recruitment of Black talent in the industry.
BioSpace
AUGUST 10, 2021
Inflammation is an important protective mechanism if it can be controlled. This is a key component of Genti’s engineering and the secret to the potency of its Tregs.
Pharma Times
AUGUST 10, 2021
Approval represents a new indication for GW's cannabidiol in the UK
BioSpace
AUGUST 10, 2021
I-Mab announced positive interim data from its U.S. Phase II/III clinical trial of plonmarlimab for treatment of cytokine release syndrome in severe COVID-19.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Pharma Times
AUGUST 10, 2021
The treatment was not recommended by NICE for the NHS in England
BioSpace
AUGUST 10, 2021
The global biopharmaceutical company said that it is well capitalized with cash, cash equivalents, restricted cash, and investments of as much as $222.8 million as of 30 June 2021.
Pharma Times
AUGUST 10, 2021
Phase III trials are ongoing in Europe and the US
BioSpace
AUGUST 10, 2021
Trying to get clinical trials enrolled and completed creates a bottleneck that has hindered drug development for years. With a fresh $220 million in hand, Reify Health is looking to change that.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
The Pharma Data
AUGUST 10, 2021
Florida A&M University, Howard University, Morgan State University, North Carolina A&T University and University of Arkansas at Pine Bluff will pioneer the program in collaboration with Bristol Myers Squibb Tomorrow’s Innovators hopes to create actionable change within the biopharma industry by improving the recruitment and retention of diverse talent and enhancing the student educational experience at participating Historically Black Colleges and Universities (HBCUs).
BioSpace
AUGUST 10, 2021
The companies will harness the power of machine learning to increase the scalability of medicines based on spirulina, a type of blue-green algae.
Drug Patent Watch
AUGUST 10, 2021
Annual Drug Patent Expirations for EXPAREL Exparel is a drug marketed by Pacira Pharms Inc and is included in one NDA. It is available from one supplier. There is one…. The post New patent for Pacira Pharms drug EXPAREL appeared first on DrugPatentWatch - Make Better Decisions.
BioSpace
AUGUST 10, 2021
BioSpace recently spoke with James Oliviero, CEO and president at Checkpoint Therapeutics, an immuno-oncology, late-stage development company.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Intouch Solutions
AUGUST 10, 2021
Every brand likely has an underrepresented audience – a demographic subgroup that is significantly impacted by a condition but is bundled into the general population without consideration of their unique motivators, barriers, or media consumption. Are you reaching yours? As marketers, our work focuses on leveraging data and technology to craft more personalized experiences for patients, caregivers, and healthcare professionals, but understanding the nuances of their experiences (which can differ
BioSpace
AUGUST 10, 2021
Women who are pregnant are more vulnerable to developing severe illness after infection with SARS-Cov-2, the novel coronavirus that causes COVID-19.
pharmaphorum
AUGUST 10, 2021
Private equity group Carlyle has said it won’t raise its offer for respiratory drug specialist Vectura to match a 165p per share offer from tobacco giant Philip Morris International (PMI). The investment firm said its 155p offer was “full and fair” and would not be raised, meaning that it would not enter into a head-to-head auction demanded by the UK’s Takeover Panel, which regulates mergers and acquisitions involving UK registered companies.
BioSpace
AUGUST 10, 2021
Emergent BioSolutions has approval to resume manufacturing vaccines, but its lawsuit issues haven’t gone away as easily.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Clinical Trial Gurus
AUGUST 10, 2021
Anytime a patient is hospitalized while in a study, a Serious Adverse Event likely occurred. This may seem obvious, but clinical research coordinators and associates should read between the lines and observe if any reference to hospitalizations have occurred in between study visits.
BioSpace
AUGUST 10, 2021
AbbVie’s Allergan Aesthetics announced it was buying Soliton in a deal worth about $550 million. Now, the Federal Trade Commission has requested additional information about the deal.
BioTech 365
AUGUST 10, 2021
Orange CA Joint Pain Digital X-Ray Diagnosis/Chiropractic Care Service Announced Orange CA Joint Pain Digital X-Ray Diagnosis/Chiropractic Care Service Announced Orange, CA Chiropractic specialist Dr.
BioSpace
AUGUST 10, 2021
Check out where the money went in the life sciences industry this week.
Advertisement
The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. Demand-led supply and direct-to-patient distribution are next-generation solutions that are helping to meet these growing needs, allowing for more streamlined processes and patient-centric studies.
Expert insights. Personalized for you.
363 
Let's personalize your content